Physician

Steven Y Liu, M.D.

According to 2025 Medicare claims, Steven Liu, M.D. (NPI: 1164462834) practices medical oncology in the Anchorage, AK market, with the plurality of this provider's patient population coming from Anchorage, AK. This provider's primary affiliated billing organization is ALASKA ONCOLOGY AND HEMATOLOGY LLC (NPI: 1487713848; TIN: 92-0175249) and primary practice location at 99508-2959.

Liu's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 560 traditional Medicare patients, billed 222,433 HCPCS/CPT codes, and received $6,461,216 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 1,087 prescription claims across 176 beneficiaries totaling $5,582,608 in drug costs, led by Revlimid (Lenalidomide). DME data shows 49 claims. Open Payments data shows 251 records totaling $2,029,531. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $1,247,703 to $6,461,216. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $547,361 to $5,582,608. In contrast, DME billing represents a smaller volume and declined steadily, from $9,102 to $2,361.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	307	87,516	$1,247,703
2016	343	91,195	$1,545,446
2017	358	107,182	$1,910,628
2018	358	101,543	$2,028,137
2019	419	107,979	$2,154,807
2020	426	154,479	$3,249,210
2021	459	183,960	$4,437,388
2022	494	216,169	$5,675,461
2023	494	217,223	$6,057,726
2024	560	222,433	$6,461,216

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	55	869	$547,361
2016	69	726	$740,685
2017	67	642	$786,087
2018	60	422	$620,517
2019	91	585	$2,213,331
2020	119	758	$2,701,556
2021	131	900	$2,621,609
2022	135	876	$2,882,169
2023	140	787	$3,219,315
2024	176	1,087	$5,582,608

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	151	$9,509
2016	N/R	142	$5,941
2017	N/R	225	$17,517
2018	N/R	209	$14,396
2019	N/R	43	$5,471
2020	N/R	76	$6,939
2021	N/R	88	$6,468
2022	N/R	48	$2,457
2023	N/R	35	$6,125
2024	N/R	49	$1,241

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	113	113	$213
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	168	270	$176
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	348	900	$120
96413	Administration of chemotherapy into vein, 1 hour or less	133	688	$108
J1100	Injection, dexamethasone sodium phosphate, 1 mg	74	2,758	$0

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	34	953	$558,968
Lenalidomide	Lenalidomide	40	1,120	$544,122
Xtandi	Enzalutamide	35	1,050	$509,013
Calquence	Acalabrutinib Maleate	29	990	$481,476
Inlyta	Axitinib	22	660	$419,640

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	16	$473
J8999	Prescription drug, oral, chemotherapeutic, nos	N	N/R	12	$392
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	21	$376

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	124	$3,045	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	127	$2,026,486	Novartis Pharmaceuticals Corporation
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Steven Y. Liu, M.D.?

Tedicare shows public-source Medicare data for Steven Y. Liu, M.D. (NPI 1164462834), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Steven Y. Liu, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Steven Y. Liu, M.D.?

Steven Y. Liu, M.D. is linked to ALASKA ONCOLOGY AND HEMATOLOGY LLC (billing NPI 1487713848) in the available physician profile data.

Does Steven Y. Liu, M.D. have Open Payments data?

Steven Y. Liu, M.D. has 251 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.